DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
SYK logo

Stryker Corporation Stock Price

NYSE:SYK Community·US$106.0b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 136 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

SYK Share Price Performance

US$275.39
-107.58 (-28.09%)
​
US$376.28
Fair Value
US$275.39
-107.58 (-28.09%)
26.8% undervalued intrinsic discount
US$376.28
Fair Value
Price US$275.39
AnalystConsensusTarget US$376.28
Tokyo US$323.52
duarte_EM US$311.21
Wed, 9 Sep 26
Fair ValueUS$376.28
Share Pricen/a

SYK Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$376.28 26.8% undervalued intrinsic discount

Aging Populations And Emerging Markets Will Transform Healthcare

2users have liked this narrative
2users have commented on this narrative
57users have followed this narrative
TO
Tokyo
Tokyo's
Fair Value
·
Fair Value US$323.52 14.9% undervalued intrinsic discount

Investing in Stryker (SYK) should be an easy ride

5users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
DU
duarte_EM's
Fair Value
·
Fair Value US$311.21 11.5% undervalued intrinsic discount

Stryker — Defensive Compounder Riding Demographics + Mako

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
SYK logo
Stryker
11.5% undervalued intrinsic discount

Stryker — Defensive Compounder Riding Demographics + Mako

View narrative
DU
duarte_EM
Published 3 Sep
Read Narrative
SYK logo
Stryker
14.9% undervalued intrinsic discount

Investing in Stryker (SYK) should be an easy ride

View narrative
TO
Tokyo
Recommended Voice
Tokyo
Published 9 May 2024
Read Narrative
SYK logo
Stryker
26.8% undervalued intrinsic discount
Updated

Aging Populations And Emerging Markets Will Transform Healthcare

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 9 Sep
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

DU
SYK logo

Stryker — Defensive Compounder Riding Demographics + Mako

Fair Value: US$311.21 11.5% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
TO
Tokyo
SYK logo

Investing in Stryker (SYK) should be an easy ride

Fair Value: US$323.52 14.9% undervalued intrinsic discount
12 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
SYK logo

SYK: Hospital Digitization And Cyber Resilience Will Underpin Post Cyberattack Recovery

Fair Value: US$376.28 26.8% undervalued intrinsic discount
57 fair values setusers have set this as their fair value
2 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Undervalued with solid track record and pays a dividend.

2 Risks
4 Rewards
View Full Analysis

Stryker Corporation Key Details

US$25.8b

Revenue

US$8.9b

Cost of Revenue

US$16.9b

Gross Profit

US$13.2b

Other Expenses

US$3.7b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
9.72
65.59%
14.43%
62.3%
View Full Analysis

About SYK

Founded
1941
Employees
56000
CEO
Kevin Lobo
WebsiteView website
www.stryker.com

Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

Recent SYK News & Updates

User avatar
New Narrative • Sep 03

Stryker — Defensive Compounder Riding Demographics + Mako

Stryker is my defensive-growth anchor: a high-quality medtech leader in orthopaedics, surgical equipment and MedSurg, riding the durable tailwind of an ageing population. Demographics, not hype, drive this thesis.

Recent updates

No updates

Stryker Corporation Competitors

UNH logo

UnitedHealth Group

Symbol: NYSE:UNH
Market cap: US$359.8b
ABT logo

Abbott Laboratories

Symbol: NYSE:ABT
Market cap: US$182.6b
ISRG logo

Intuitive Surgical

Symbol: NasdaqGS:ISRG
Market cap: US$123.7b
CVS logo

CVS Health

Symbol: NYSE:CVS
Market cap: US$122.9b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide